The FDA is investigating reports of patients developing blood cancer after receiving bluebird bio’s gene therapy Skysona ...
Former FDA commissioner Scott Gottlieb is raising concerns with Senate Republicans about the president-elect’s selection of ...
The FDA granted approval to nilotinib (Danziten) on November 14, 2024, for the treatment of adult patients with newly ...
Given how the U.S. Supreme Court’s conservative majority is better known for limiting the authority of federal regulatory ...
Executives at Applied Therapeutics told analysts they were surprised by the agency’s refusal to approve the company’s treatment for classic galactosemia.
The FDA has rejected Applied Therapeutics’ attempt to win approval on the strength of a failed phase 3 trial, triggering a 75% drop in the biotech’s share price. Applied said the complete response ...
Products sold in the Northwest have been given the highest risk status, but so far no illnesses have been reported.
Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/90.BMDkfsfZ.js ...